Robert N. Taub

3.3k total citations
79 papers, 2.3k citations indexed

About

Robert N. Taub is a scholar working on Pulmonary and Respiratory Medicine, Immunology and Molecular Biology. According to data from OpenAlex, Robert N. Taub has authored 79 papers receiving a total of 2.3k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Pulmonary and Respiratory Medicine, 19 papers in Immunology and 18 papers in Molecular Biology. Recurrent topics in Robert N. Taub's work include Occupational and environmental lung diseases (19 papers), Pleural and Pulmonary Diseases (14 papers) and Immunotherapy and Immune Responses (7 papers). Robert N. Taub is often cited by papers focused on Occupational and environmental lung diseases (19 papers), Pleural and Pulmonary Diseases (14 papers) and Immunotherapy and Immune Responses (7 papers). Robert N. Taub collaborates with scholars based in United States, Canada and United Kingdom. Robert N. Taub's co-authors include Eugene M. Lance, Alexander Hindenburg, Michael A. Baker, Kapil N. Bhalla, Mary Louise Keohan, Mary Hesdorffer, Steven Grant, James E. Gervasoni, Alain Borczuk and Valerie Stewart and has published in prestigious journals such as Nature, New England Journal of Medicine and Journal of Clinical Investigation.

In The Last Decade

Robert N. Taub

77 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Robert N. Taub United States 27 722 718 684 513 300 79 2.3k
Raymond Tubbs United States 28 936 1.3× 815 1.1× 375 0.5× 706 1.4× 302 1.0× 72 2.5k
Bruce Ng United States 18 1.0k 1.4× 484 0.7× 529 0.8× 657 1.3× 202 0.7× 29 2.1k
Dietmar Berger Germany 28 582 0.8× 622 0.9× 592 0.9× 353 0.7× 395 1.3× 66 2.8k
Fumitaka Ogushi Japan 25 453 0.6× 547 0.8× 718 1.0× 365 0.7× 182 0.6× 116 2.1k
Masaki Tomita Japan 25 908 1.3× 527 0.7× 589 0.9× 366 0.7× 273 0.9× 119 2.0k
T. Ming Chu United States 24 625 0.9× 556 0.8× 849 1.2× 311 0.6× 337 1.1× 53 2.1k
Kuniyuki Oka Japan 24 629 0.9× 413 0.6× 405 0.6× 264 0.5× 348 1.2× 101 1.8k
Jules E. Harris United States 26 1.8k 2.6× 788 1.1× 506 0.7× 1.0k 2.0× 472 1.6× 84 3.3k
Stefanie Hammer Germany 23 545 0.8× 835 1.2× 322 0.5× 180 0.4× 216 0.7× 63 2.1k
Michael Kraut United States 24 832 1.2× 489 0.7× 1.0k 1.5× 179 0.3× 254 0.8× 58 1.9k

Countries citing papers authored by Robert N. Taub

Since Specialization
Citations

This map shows the geographic impact of Robert N. Taub's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert N. Taub with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert N. Taub more than expected).

Fields of papers citing papers by Robert N. Taub

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert N. Taub. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert N. Taub. The network helps show where Robert N. Taub may publish in the future.

Co-authorship network of co-authors of Robert N. Taub

This figure shows the co-authorship network connecting the top 25 collaborators of Robert N. Taub. A scholar is included among the top collaborators of Robert N. Taub based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert N. Taub. Robert N. Taub is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Bhatt, Nikunj, Mikhail Doubrovin, Catherine S. Spina, et al.. (2022). Preliminary efficacy of [90Y]DOTA-biotin-avidin radiotherapy against non-muscle invasive bladder cancer. European Journal of Nuclear Medicine and Molecular Imaging. 50(3). 692–700. 1 indexed citations
2.
Leinwand, Joshua, Robert N. Taub, John A. Chabot, & Michael D. Kluger. (2019). Two-Stage Cytoreductive Surgery and Intraperitoneal Chemotherapy for Diffuse Malignant Peritoneal Mesothelioma: Predictors of Overall Survival in an Intention-to-Treat Series. Annals of Surgical Oncology. 27(7). 2539–2547. 9 indexed citations
3.
Hesdorffer, Mary, et al.. (2016). Approach to offering remote support to mesothelioma patients: the mesothelioma survivor project. Translational Lung Cancer Research. 5(3). 216–218. 2 indexed citations
4.
Borczuk, Alain, Jianming Pei, Robert N. Taub, et al.. (2016). Genome-wide analysis of abdominal and pleural malignant mesothelioma with DNA arrays reveals both common and distinct regions of copy number alteration. Cancer Biology & Therapy. 17(3). 328–335. 38 indexed citations
5.
Hesdorffer, Mary, John A. Chabot, Mary Louise Keohan, et al.. (2008). Combined Resection, Intraperitoneal Chemotherapy, and Whole Abdominal Radiation for the Treatment of Malignant Peritoneal Mesothelioma. American Journal of Clinical Oncology. 31(1). 49–54. 42 indexed citations
6.
Hesdorffer, Mary, et al.. (2008). Peritoneal Mesothelioma. Current Treatment Options in Oncology. 9(2-3). 180–190. 25 indexed citations
7.
Taylor, Clare, Dawn L. Hershman, Nina Shah, et al.. (2007). Augmented HER-2–Specific Immunity during Treatment with Trastuzumab and Chemotherapy. Clinical Cancer Research. 13(17). 5133–5143. 167 indexed citations
8.
Taub, Robert N., et al.. (2007). New Strategies for Treating GIST When Imatinib Fails. Cancer Investigation. 25(5). 328–335. 5 indexed citations
9.
10.
Saqi, Anjali, et al.. (2005). Utility of CD138 (syndecan‐1) in distinguishing carcinomas from mesotheliomas. Diagnostic Cytopathology. 33(2). 65–70. 12 indexed citations
11.
Talbot, Susan, Cathryn Rankin, Robert N. Taub, et al.. (2003). High‐dose ifosfamide with mesna and granuloctye–colony‐stimulating factor (recombinant human G‐CSF) in patients with unresectable malignant mesothelioma. Cancer. 98(2). 331–336. 3 indexed citations
12.
Talbot, Susan, Mary Louise Keohan, Mary Hesdorffer, et al.. (2003). A phase II trial of temozolomide in patients with unresectable or metastatic soft tissue sarcoma. Cancer. 98(9). 1942–1946. 64 indexed citations
13.
Dutoit, Valérie, Robert N. Taub, Kyriakos P. Papadopoulos, et al.. (2002). Multiepitope CD8+ T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. Journal of Clinical Investigation. 110(12). 1813–1822. 9 indexed citations
14.
Talbot, Susan, Robert N. Taub, Mary Lou Keohan, et al.. (2002). Combined heart and lung transplantation for unresectable primary cardiac sarcoma. Journal of Thoracic and Cardiovascular Surgery. 124(6). 1145–1148. 62 indexed citations
15.
Taub, Robert N., et al.. (2000). Peritoneal mesothelioma. Current Treatment Options in Oncology. 1(4). 303–312. 21 indexed citations
16.
Stein, C.A., John L. Tonkinson, Liming Zhang, et al.. (1993). Dynamics of the internalization of phosphodiester oligodeoxynucleotides in HL60 cells. Biochemistry. 32(18). 4855–4861. 143 indexed citations
17.
Schanzer, Harry, et al.. (1977). Prolongation of Rat Renal Allograft Survival by Cyclophosphamide and Intravenous Donor-Specific Antigens. European Surgical Research. 9(2). 140–154. 2 indexed citations
18.
Taub, Robert N., et al.. (1972). DISTRIBUTION OF LABELED LYMPH NODE CELLS IN MICE DURING THE LYMPHOCYTOSIS INDUCED BY BORDETELLA PERTUSSIS . The Journal of Experimental Medicine. 136(6). 1581–1593. 34 indexed citations
19.
Severin, C, et al.. (1972). ADAPTATION OF SKIN ALLOGRAFTS IN MICE TREATED WITH ANTILYMPHOCYTE SERUM. Transplantation. 13(1). 27–30. 4 indexed citations
20.
Taub, Robert N. & Eugene M. Lance. (1968). HISTOPATHOLOGICAL EFFECTS IN MICE OF HETEROLOGOUS ANTILYMPHOCYTE SERUM. The Journal of Experimental Medicine. 128(6). 1281–1307. 68 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Raymond Tubbs Breakdown of academic impact, for papers by Bruce Ng Breakdown of academic impact, for papers by Dietmar Berger Breakdown of academic impact, for papers by Fumitaka Ogushi Breakdown of academic impact, for papers by Masaki Tomita Breakdown of academic impact, for papers by T. Ming Chu Breakdown of academic impact, for papers by Kuniyuki Oka Breakdown of academic impact, for papers by Jules E. Harris Breakdown of academic impact, for papers by Stefanie Hammer Breakdown of academic impact, for papers by Michael Kraut
Rankless by CCL
2026